Evaxion to present preclinical Proof-of-Concept for precision ERV cancer vaccine concept at ESMO Immuno-Oncology Congress
02 déc. 2024 08h00 HE
|
Evaxion Biotech
COPENHAGEN, Denmark, December 2, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present...
Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform
03 oct. 2024 08h00 HE
|
Evaxion Biotech
Improved precision of the AI-Immunology™ platform in predicting clinically relevant vaccine targets boosts the potential of its AI-derived vaccine candidates The improvement has been achieved through...
Edete Precision Technologies Wins 2024 AgTech Breakthrough Award For “AgTech Implementation of the Year”
21 août 2024 08h00 HE
|
AgTech Breakthrough
LOS ANGELES, Aug. 21, 2024 (GLOBE NEWSWIRE) -- AgTech Breakthrough, a leading market intelligence organization that recognizes the top companies, technologies and products in the global agricultural...
Revolution Medicines Completes Acquisition of EQRx
09 nov. 2023 09h10 HE
|
Revolution Medicines, Inc.
Acquisition Expected to Add Approximately $1.1 Billion in Net Cash to Revolution Medicines’ Balance Sheet, Supporting Late-Stage Development of RAS(ON) Inhibitor Investigational Drugs Sandra Horning,...
HistoSonics Edison System Recognized With BioTech Breakthrough Award For “MedTech Innovation Of The Year”
08 nov. 2023 08h02 HE
|
BioTech Breakthrough
LOS ANGELES, Nov. 08, 2023 (GLOBE NEWSWIRE) -- BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology...
Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress
06 nov. 2023 16h05 HE
|
Revolution Medicines, Inc.
Promising clinical data for RMC-6236, a RASMULTI(ON) Inhibitor, and RMC-6291, a RASG12C(ON) Inhibitor, presented at AACR-NCI-EORTC (“Triple”) and ESMO Meetings Acquisition of EQRx, Inc. expected to...
Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236
22 oct. 2023 02h30 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Oct. 22, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
[Latest] Global Precision Fermentation Market Size/Share Worth USD 25.54 Billion by 2032 at a 45% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
09 oct. 2023 18h30 HE
|
Custom Market Insights
Austin, TX, USA, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Precision Fermentation Market Size, Trends and Insights By Ingredient (Whey...
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor
19 sept. 2023 07h00 HE
|
Revolution Medicines, Inc.
KRASG12D(ON) Inhibitor with highly differentiated mechanism of action being evaluated in patients with cancers harboring the KRASG12D mutation, the most common driver of RAS-addicted human cancers ...
Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins
17 août 2023 16h05 HE
|
Revolution Medicines, Inc.
Science Report on KRASG12C(ON)-Selective Inhibitors Provides Preclinical Proof-of-Principle for Company's RAS Innovation Engine and Broad Pipeline REDWOOD CITY, Calif., Aug. 17, 2023 (GLOBE...